Spots Global Cancer Trial Database for Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Official Title: Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Study ID: NCT03134131
Conditions
Interventions
Study Description
Brief Summary: The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.
Detailed Description:
Keywords
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Oncoceutics, Philadelphia, Pennsylvania, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
